ClinicalTrials.gg
Not yet recruitingNCT07901088Updated Oct 28, 2026

A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions

A Phase 1 interventional study of Test Drug and Reference Drug in Peripheral Arterial Disease, sponsored by AJU Pharm Co., Ltd.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AJU Pharm Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of — 9 open to participants now, 9 under way, 2 of them phase 3. Peripheral Arterial Disease · Korea, Republic of.

Planned enrollment
26th of 31
40 · median 230
Started
2026
with 1 other
Phase 1
4 of 41
1 open now
Registered
41st of 41
by date
Lead sponsor
1 of 41
AJU Pharm Co., Ltd.

Among the 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of, this one is the 26th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 1, and was the 41st registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

9 of the 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To evaluate the bioequivalence and safety of AJU-B718 and B718R in Healthy Adults.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 19 to less than 65 years at screening.
  • Healthy adults without congenital or chronic diseases.
  • Considered eligible based on screening test results.
  • 18 to 30 kg/m², with body weight ≥50 kg for males and ≥45 kg for females.
  • Provided written .
  • Willing to comply with the specified and reproductive restrictions.

Exclusion criteria

Exclusion Criteria:

  • Use of prohibited or potentially interfering medications within the specified period prior to the first administration.
  • Excessive alcohol consumption within 1 month prior to the first administration.
  • Participation in another clinical trial involving administration of an product within 6 months prior to the first administration.
  • Blood donation within the specified period prior to the first administration.
  • History of gastrointestinal surgery that may affect drug absorption.
  • bleeding disorders or other medical conditions that may affect study participation.
  • History of clinically significant psychiatric disorders.
  • Considered unsuitable for study participation by the Investigator or delegated physician.
  • Pregnancy, suspected pregnancy, or breastfeeding in female participants.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Period 1: Reference Drug, Single dose / Period 2: Test Drug, Single dose / Period 3: Reference Drug, Single dose / Period 4: Test Drug, Single dose

    Drug: Test Drug · Drug: Reference Drug

  • Experimental
    Sequence B

    Period 1: Test Drug, Single dose / Period 2: Reference Drug, Single dose / Period 3: Test Drug, Single dose / Period 4: Reference Drug, Single dose

    Drug: Test Drug · Drug: Reference Drug

Interventions

  • DrugTest Drug

    AJU-B718

  • DrugReference Drug

    B718R

06

What researchers measure

Primary outcomes

  1. AUCt of AJU-B718

    Time frame: Pre-dose(0 hours) ~ 24 hours

  2. Cmax of AJU-B718

    Time frame: Pre-dose(0 hours) ~ 24 hours

Secondary outcomes

  1. AUCinf of AJU-B718

    Time frame: Pre-dose(0 hours) ~ 24 hours

  2. Tmax of AJU-B718

    Time frame: Pre-dose(0 hours) ~ 24 hours

  3. t1/2 of AJU-B718

    Time frame: Pre-dose(0 hours) ~ 24 hours

  4. AUCt/AUCinf of AJU-B718

    Time frame: Pre-dose(0 hours) ~ 24 hours

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.

Of 26 phase 1 interventional studies under Peripheral Arterial Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2026
First posted
Oct 28, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07901088
Responsible party
Sponsor
First posted
Oct 28, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion